Brent crude oil prices recovered to around $109.78 per barrel amid renewed concerns over supply disruptions in the Middle East, following unconfirmed attacks on Saudi energy sites by Yemen’s Houthis. The risk of supply interruptions in the Gulf remains the key factor driving oil prices higher. However, potential increases in Russian fuel exports due to a U.S. sanctions waiver could limit price gains. Technical analysis suggests Brent could break above $110 and move towards $120 if supply fears persist, while WTI oil may rise above $106 towards $110. The market remains cautious, balancing supply risks against possible easing from increased Russian exports and safer Gulf shipping conditions.
Brent crude oil price forecasts provide context with Pluang's Energy sector data as of Oct 20, 2026 07:11 WIB. Of 79 priced Energy-sector US stocks, 27 rose and 51 fell. Notable movers include RIG at USD 5.89 with a 4.80% increase and 100% buy order activity, LEU at USD 110.14 down 4.18% with 72% buy orders, and PBF at USD 81.43 down 3.66% with full buy orders. Typical hold times vary from 2 to 31 days.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
Ripple Prime plans to back the launch of Securitize Stocks, a new tokenized U.S. stock product issued on-chain, allowing eligible investors in the U.S., EU, and other markets to receive dividends and voting rights. Ripple Prime, which evolved from Ri...
A video shared by The Bitcoin Historian quotes an unnamed wealth adviser who encourages clients to obtain one Bitcoin, believing it could increase in value by 100 times. The adviser also notes that institutional adoption and understanding of Bitcoin ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
